Product logins

Find logins to all Clarivate products below.


In 2023, sales of branded MAb biologics in neurology exceeded $10 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2023-2033 forecast period, the reference brands Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) are set to lose patent protection, and biosimilars will enter the market and erode both patient share and drug prices. We present our forecasts for these key reference brands and their biosimilars by molecule and country / region.

Related Market Assessment Reports

Report
Alzheimer’s Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)
Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s Kisunla (donanemab) have launched for the treatment of early Alzheimer’s disease (AD) in the United States and Japan and, after early…
Report
Epilepsy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy…
Report
Myasthenia Gravis – Unmet Need – Unmet Need – Generalized Myasthenia Gravis (US/EU)
Myasthenia gravis (MG) is a rare autoimmune disorder in which antibodies impair acetylcholinemediated neuromuscular transmission, causing fluctuating muscle weakness. Generalized MG (gMG) often…
Report
Parkinson’s Disease – Current Treatment – Current Treatment: Physician Insights – Parkinson’s Disease (US)
The mature Parkinson’s disease treatment market continues to evolve as newly launched pump therapies (i.e., AbbVie’s Vyalev, Supernus’s Onapgo), extended-release levodopa formulations (i.e.,…
Report
Epilepsy – Unmet Need – Unmet Need – Epilepsy: Generalized-Onset Seizures (US/EU)
Generalized onset seizures (GOS) originate simultaneously in both hemispheres of the brain and account for nearly 40% of all epilepsy cases. Current management relies primarily on widely used…